A Phase Ib/II Study Combining Chemotherapy and Immunotherapy for the Treatment of Non-Hodgkin Lymphoma

Full Title

A Phase Ib/II Study Evaluating the Safety and Efficacy of MPDL3280A in Combination with Either Obinutuzumab plus Bendamustine or Obinutuzumab Plus CHOP In Patients With Follicular Lymphoma Or Diffuse Large B-cell Lymphoma


The drug rituximab is commonly used to treat follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). It is often given in combination with another drug called bendamustine or with a four-drug chemotherapy regimen called CHOP. Rituximab works by binding to a protein on lymphoma cells called CD20. Despite this therapy, however, patients’ cancers often come back. Doctors are therefore seeking more effective treatments.

In this study, researchers are evaluating the safety of two different drug combinations for follicular lymphoma and DLBCL:

  • CHOP plus obinutuzumab and atezolizumab (MPDL3280A)
  • Bendamustine plus obinutuzumab and atezolizumab

Like rituximab, obinutuzumab triggers an immune response against cancer by targeting CD20, but its ability to do so is stronger than rituximab. Obinutuzumab is already approved for treating chronic lymphocytic leukemia.

Atezolizumab is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. It is approved for treating bladder and cancers; its use in this study is considered investigational.

Both drugs are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have CD20-positive follicular lymphoma or DLBCL. Patients may be newly diagnosed or may have previously received treatment.
  • Patients must recover from the side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Anas Younes at 212-639-5059.